Cooper Companies Bundle
Who owns CooperCompanies today?
CooperCompanies evolved from Cooper Laboratories (1958) into a global eye‑care and women’s health device firm headquartered in San Ramon, CA. The 2014 Sauflon acquisition boosted CooperVision and shifted institutional ownership higher. As of fiscal 2024, revenue was about $3.7–3.9 billion.
Ownership is widely held by public and institutional investors with no controlling family; major mutual funds and ETFs increased stakes after the Sauflon deal. See Cooper Companies Porter's Five Forces Analysis for strategic context.
Who Founded Cooper Companies?
CooperCompanies began as Cooper Laboratories in 1958, founded by Martin H. 'Marty' Cooper and A. Edward 'Ed' Schantz, focused on medical devices and diagnostics; early ownership was concentrated among the founders, a handful of early employees and private backers. Public records show a founder‑led common‑share structure with standard vesting and buy‑sell arrangements typical of that era.
Founding principals
Martin H. 'Marty' Cooper and A. Edward 'Ed' Schantz founded Cooper Laboratories in 1958 with a clinical device and diagnostics focus.
Early capitalization
Initial equity was held by founders, early employees and private investors; specific percentage splits at inception are not publicly documented.
Governance model
Corporate governance reflected founder‑led control with common shares and standard vesting/buy‑sell provisions common in the 1950s–1970s.
Growth strategy
1960s–1970s expansion relied on product development and small acquisitions, gradually broadening the shareholder base ahead of later public listings.
Dilution over time
Founder stakes diminished materially by subsequent restructurings; by the 1990s no enduring founder control remained.
Legacy vision
The founding vision to commercialize clinically useful eye care and women's health devices persisted even as equity control shifted to public markets and institutions.
Early records do not show major founder ownership disputes; institutional ownership and public shareholders later became primary holders of Cooper Companies stock as the company scaled and successor entities listed publicly.
Key facts on founders and early ownership
Founders, early ownership structure and transition to public holders — concise points for investors researching who owns Cooper Companies and Cooper Companies shareholders.
- Founded in 1958 by Martin H. 'Marty' Cooper and A. Edward 'Ed' Schantz.
- Initial ownership concentrated among founders, early employees and private backers; no public inception split data.
- By the 1990s founder control had effectively dissipated; institutional investors became dominant.
- For governance and modern ownership details see the Revenue Streams & Business Model of Cooper Companies
Cooper Companies SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Cooper Companies’s Ownership Changed Over Time?
Key inflection points reshaped Cooper Companies ownership: CooperVision’s 2000s consolidation, the 2011 groundwork and the transformative 2014 Sauflon Pharmaceuticals deal (~$1.2 billion), and CooperSurgical’s 2016–2023 fertility/women’s health roll‑up including the Origio era and the 2021 Generate Life Sciences purchase (~$1.6 billion), driving higher index fund weights and institutional ownership.
| Year / Event | Ownership Impact |
|---|---|
| 2000s — CooperVision growth | Revenue scale increased institutional interest; lens business drove core free cash flow |
| 2014 — Sauflon Pharmaceuticals (~$1.2 billion) | Material boost to lens revenues; index fund inclusion and passive ownership rose |
| 2016–2023 — CooperSurgical M&A (Origio, Generate Life Sciences) | Expanded company size; increased market cap and index weighting; Generate deal (~$1.6 billion) notable |
By FY2024 CooperCompanies reported diluted shares outstanding near 49–50 million, with free float approaching 100%, and no strategic corporate or government owner disclosed.
Major shareholders and trends
Institutional and index funds dominate ownership, shaping governance and capital allocation toward ROIC expansion in lenses and selective women’s‑health investments.
- Vanguard Group frequently holds ~10–12% of shares
- BlackRock typically around 8–10%
- State Street/SSGA often in the 4–6% range
- Capital Group, T. Rowe Price, Wellington, Fidelity commonly appear in the 1–5% range
Insider ownership is modest, generally under 2% combined with individual executives usually below 1%; governance remains one‑share‑one‑vote under institutional oversight and index stewardship. For ownership history and investor mix read this detailed piece on the company’s market positioning: Target Market of Cooper Companies
Cooper Companies PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Cooper Companies’s Board?
As of 2024–2025, CooperCompanies' board is majority independent with the CEO serving as a director; members bring medical device, healthcare and finance expertise. The company follows a one‑share‑one‑vote structure without dual‑class or golden share provisions.
| Director | Role / Background | Independence |
|---|---|---|
| CEO (name withheld) | Executive — Senior management, company operations | Non‑independent |
| Independent Director A | Medical device / clinical leadership | Independent |
| Independent Director B | Healthcare strategy / payer experience | Independent |
| Independent Director C | Finance / audit committee expertise | Independent |
Voting power aligns with economic ownership; no single shareholder holds an outsized controlling block, and large institutional owners engage through governance outreach rather than reserved board seats.
Board composition and shareholder influence
CooperCompanies employs a standard voting structure and a dispersed shareholder base, so institutional coalitions can sway governance but no entrenched founder control exists.
- One‑share‑one‑vote structure; no dual‑class or super‑voting shares
- Majority independent board with CEO as director; directors drawn from medical, healthcare and finance fields
- Shareholder proposals focus on ESG disclosure, executive pay alignment and product safety oversight
- No recent public proxy contests causing board turnover; institutional owners (e.g., Vanguard, BlackRock, large mutual funds) are sizable but do not singularly control voting
Latest filings (2024 proxy / 13F data) show institutional ownership at approximately 60–70% of shares outstanding, with top institutional holders typically including Vanguard and BlackRock; insider ownership remains low single digits, and voting outcomes reflect proportional economic ownership—see ownership breakdown and registry sources for specifics and the company’s governance disclosures and this Brief History of Cooper Companies.
Cooper Companies Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Cooper Companies’s Ownership Landscape?
From 2019 through 2024, Cooper Companies ownership shifted toward passive and institutional holders as market cap and index weights rose; Vanguard and BlackRock modestly increased stakes in line with passive fund flows, while insider ownership remained low and activist pressure was limited.
| Period | Key Ownership Trend | Notable Impact |
|---|---|---|
| 2019–2020 | Rising passive ownership; steady buyback use | Net diluted shares held near 48–50M |
| 2021–2022 | Leverage spike after Generate acquisition (~$1.6B) then deleveraging | Credit-sensitive funds showed interest; equity holders stayed dominant |
| 2023–2025 | Strong institutional inflows tied to CooperVision silicone hydrogel and MiSight growth | Support for valuation and continued low insider ownership |
Share repurchases have been used periodically to offset stock-compensation dilution, keeping diluted shares roughly stable through FY2024; guidance centers on organic growth, margin expansion, and portfolio optimization rather than privatization.
Passive ownership rise
Index inclusion and market-cap growth increased passive funds' weight; Vanguard and BlackRock raised positions modestly in line with fund flows.
Buybacks vs dilution
Company maintained buyback authorizations; diluted shares remained around high‑40 million through FY2024 despite stock compensation.
Generate Life Sciences deal
The ~$1.6B CooperSurgical acquisition in 2021 temporarily raised leverage; subsequent EBITDA growth reduced leverage and attracted credit‑sensitive funds.
Product-led institutional interest
CooperVision momentum in silicone hydrogel dailies and MiSight myopia management (2023–2025) supported institutional ownership and valuation stability.
For ownership context and historical analysis, see Marketing Strategy of Cooper Companies
Cooper Companies Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Cooper Companies Company?
- What is Competitive Landscape of Cooper Companies Company?
- What is Growth Strategy and Future Prospects of Cooper Companies Company?
- How Does Cooper Companies Company Work?
- What is Sales and Marketing Strategy of Cooper Companies Company?
- What are Mission Vision & Core Values of Cooper Companies Company?
- What is Customer Demographics and Target Market of Cooper Companies Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.